<DOC>
	<DOCNO>NCT01159301</DOCNO>
	<brief_summary>This phase I trial study side effect best dose entinostat give together sorafenib tosylate treat patient advanced metastatic solid tumor refractory relapse acute myeloid leukemia . Entinostat sorafenib tosylate may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Entinostat Sorafenib Tosylate Treating Patients With Advanced Metastatic Solid Tumors Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum-tolerated dose entinostat combination sorafenib tosylate patient advance , inoperable , metastatic solid tumor . II . To determine safety tolerability regimen patient . SECONDARY OBJECTIVES : I . To determine pharmacokinetic profile regimen patient refractory/relapsed acute myeloid leukemia ( AML ) . II . To assess preliminary anti-tumor activity regimen patient advance , inoperable , metastatic solid tumor refractory/relapsed AML . III . To evaluate histone deacetylase ( HDAC ) inhibition histone acetylation leukemia blast cell . TERTIARY OBJECTIVES ( EXPLORATORY ) : I . To evaluate expression downstream marker drug activity p38 , MCL-1 , FLT-3 , VEGFR-2 leukemia blast cell . II . To evaluate SNDX-induced expression p21^WAF1/CIP1 leukemia blast cell . OUTLINE : This multicenter , dose-escalation study entinostat . Patients receive oral entinostat daily day 1 15 oral sorafenib tosylate twice daily day 1-28 ( day 15-28 course 1 ) . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients expansion cohort undergo blood , bone marrow aspiration , biopsy pharmacokinetic study biomarker analysis . After completion study therapy , patient follow 24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Must meet 1 follow criterion : Histologically cytologically confirm solid tumor ( doseescalation ) Locally advanced , inoperable , metastatic disease Evaluable measurable disease Diagnosis acute myeloid leukemia ( AML ) standard therapy , include stem cell transplantation , expect result meaningful clinical response ( expansion cohort ) Refractory relapse disease Chronic myelogenous leukemia blast crisis allow No acute promyelocytic leukemia ( 15 ; 17 ) Must consent fresh tumor , bone marrow aspirate , biopsy obtain No untreated , symptomatic , unstable brain metastases No active CNS involvement patient AML ECOG performance status 01 ANC ≥ 1,500/mm³ ( doseescalation ) Platelet count ≥ 100,000/mm³ ( doseescalation ) Hemoglobin ≥ 10 g/dL ( doseescalation ) Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 3 time ULN ( ≤ 5 time ULN liver metastasis ) Creatinine clearance ≥ 40 mL/min Albumin &gt; 3.0 g/dL Plasma phosphorus &gt; low limit normal ( supplementation ) INR ≤ 1.5 APTT ≤ 1.5 time ULN ( anticoagulant ) Able swallow oral medication ≥ 16 year old ( expanded cohort patient recruit University Colorado site ) Must tolerate prior sorafenib tosylate ( dose : 400 mg twice daily ) , applicable Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception study 90 day completion study therapy No history cardiac disease , include follow : NYHA class IIIV congestive heart failure Active coronary artery disease Prior diagnosis bradycardia cardiac arrhythmia define ≥ grade 2 uncontrolled hypertension Myocardial infarction ( MI ) within past 6 month Persistent tachycardia LVEF &lt; 40 % MUGA Second thirddegree heart block QTc &gt; 490 msec STT wave change consistent acute MI acute ischemia No clinically active serious infection define ≥ grade 2 No substance abuse , medical , psychological , social condition may , opinion Investigator , interfere patient 's participation evaluation study result No condition unstable could jeopardize safety patient his/her study compliance No known HIV infection No significant gastrointestinal disorder , opinion Investigator , could interfere absorption entinostat and/or sorafenib tosylate include follow : Significant , uncontrolled inflammatory bowel disease Abdominal fistula gastrointestinal perforation within past 6 month Extensive small bowel resection Requiring tube feed parenteral hydration and/or nutrition No concurrent immunosuppressive therapy , include highdose systemic corticosteroid ( &gt; 0.5 mg/kg/day prednisone equivalent ) unless use intermittently tapered course ≤ 4 week Concurrent hydroxyurea and/or anagrelide allow Concurrent warfarin allow provide dose stable past 2 month INR 2 3 More 4 week since prior chemotherapy , immunotherapy , investigational agent ( = &lt; 2 week leukemia patient expansion cohort ) More 2 week since prior palliative radiotherapy More 4 week since major surgery More 2 week since minor surgery ( e.g. , talc pleurodesis , excisional biopsy , etc . ) Concurrent hormonal therapy ( e.g. , LHRH antagonists , megestrol , octreotide , calcitonin , etc . ) allow No concurrent strong CYP3A4 inducer inhibitor , include , limited , follow : Valproic acid Rifampin Phenobarbital Phenytoin Carbamazepine Ketoconazole Erythromycin Grapefruit No concurrent anticancer therapy include chemotherapy , radiotherapy ( include palliative ) , immunotherapy ( except hydroxyurea leukemia patient course 1 ) No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>